← All trials
NCT03189160
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2016
- Primary completion
- Mar 1, 2018
- Completion date
- —
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- GeneScience Pharmaceuticals Co., Ltd.Lead sponsor
- Capital Medical UniversityCollaborator
- Capital Medical UniversityOverall official - principal investigator
- Jilin UniversityCollaborator
- Fudan UniversityCollaborator
- Nanjing Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Jiangxi Children's HospitalCollaborator
- Jiangnan UniversityCollaborator
- Jiao Tong UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.